<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000468781"><TermName>oregovomab</TermName><TermPronunciation>(oh-reh-GOH-voh-mab)</TermPronunciation><TermDefinition><DefinitionText>A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. Oregovomab binds to the CA-125 antigen, which is found on most ovarian cancer cells. Also called OvaRex.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000716829" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;oregovomab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000716828" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;oregovomab&quot;" language="es" id="_4"/><SpanishTermName>oregovomab</SpanishTermName><SpanishTermDefinition><DefinitionText>Anticuerpo monoclonal en estudio para el tratamiento del cáncer de ovarios. Los anticuerpos monoclonales se producen en el laboratorio y pueden localizar sustancias en el cuerpo y unirse a ellas, por ejemplo a las células cancerosas. El oregovomab se une al antígeno CA-125, que se encuentra en la mayoría de las células cancerosas del ovario. También se llama OvaRex.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-10-14</DateFirstPublished><DateLastModified>2008-01-30</DateLastModified></GlossaryTerm>
